Sort:  

🧵 2. Pharmaceutical companies challenge the unconstitutional nature of the IRA’s drug price controls, citing coercion to accept massive discounts.

🧵 3. The program targets 60 successful medications with the first 10 drugs selected for price controls, affecting treatments for various health conditions.

🧵 4. Estimated impact of the IRA includes a loss of new drugs over 30 years, leading to potential reduction in drug development and years of life lost.

🧵 5. While the government argues participation in the DPNP is voluntary due to Medicare's role, pharmaceutical companies face significant pressure to comply.